

16 March 2009

IS Pharma plc ("IS Pharma")

IS Pharma announces successful completion of European Mutual Recognition Procedure for  
Haemopressin® / Variquel™

IS Pharma plc (AIM: ISPH), the international speciality pharmaceutical company, is pleased to announce the successful conclusion of the European Mutual Recognition Procedure (MRP) for Haemopressin® / Variquel™. Completion of this phase is the precursor to the grant of marketing authorisations across a further 14 European territories. As a key critical care brand, it will be indicated for use in the treatment of bleeding oesophageal varices.

Within Europe, Haemopressin® / Variquel™ is already marketed in Germany, Austria and Switzerland. Commercialisation of the brand across the remaining 14 territories will commence during the next financial year. It is also in the registration process in the US where it has been granted orphan drug and fast track status.

IS Pharma secured the brand in April 2008 as part of its acquisition of Speciality European Pharma International AG. Since then, IS Pharma has successfully integrated the acquisition, directed Haemopressin® / Variquel™ through MRP as well as recently announcing the receipt of a \$1.25 million payment on appointment of a US commercialisation partner.

Haemopressin® / Variquel™ is a key global brand for IS Pharma and the granting of this MRP approval and the subsequent launches across Europe will significantly increase the sales potential in a global market that is estimated to be £50 million - £70 million.

Tim Wright, CEO of IS Pharma, said:

"We are delighted to have completed the European Mutual Recognition Procedure for Haemopressin® / Variquel™ on schedule, which will now enable us to commence the launch of the brand in a further 14 territories in the coming year."

"This approval marks the achievement of another significant milestone in our growth and further validates our strategy as we again demonstrate the company's ability to acquire, internationalise and organically grow brands to deliver shareholder value."

-End-

About IS Pharma plc (AIM: ISPH)

IS Pharma (International Speciality Pharmaceuticals) is a fast growing, profitable business which develops, acquires and commercialises late-stage pharmaceuticals and medical devices, focusing in critical care, oncology and neurology. Based in the UK, IS Pharma commercialises its portfolio in the UK directly and internationally through a strong network of distributors.

To find out more please go to [www.ispharma.plc.uk](http://www.ispharma.plc.uk).

Enquiries:

